Close

Alnylam Pharma (ALNY) Announces Strong Fitusiran Phase 1 Part D Data in Hemophilia A and B

December 5, 2016 6:45 AM EST Send to a Friend
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) announced positive interim results from Part D of its ongoing Phase 1 study with fitusiran ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login